Jamali, Abbas <br/><br/>
A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.  [electronic resource] 

 -  International immunology  Mar 2009 
 - 217-25 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1460-2377 
<br/><br/><label>Standard No.: </label>10.1093/intimm/dxn139  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Animals<br/>Cell Proliferation--drug effects<br/>Cytotoxicity, Immunologic--drug effects<br/>Herpes Simplex--immunology<br/>Herpesvirus 1, Human--immunology<br/>Hypersensitivity, Delayed--prevention & control<br/>Immunity, Cellular--drug effects<br/>Immunization, Secondary<br/>Immunoglobulin G--blood<br/>Mice<br/>Mice, Inbred BALB C<br/>Naloxone--administration & dosage<br/>Narcotic Antagonists--administration & dosage<br/>T-Lymphocytes, Cytotoxic--cytology<br/>Th1 Cells--immunology<br/>Vaccines, DNA--administration & dosage<br/>Viral Envelope Proteins--administration & dosage